Dr. Jennifer Buell serves as Agenus’ President and Chief Operating Officer. Since joining Agenus, Jennifer has served as the Head of Global R&D operations, Head of Research, and Chief Communications and External Affairs Officer. She has expanded Agenus from a neoantigen vaccine platform company to a global, fully-integrated company with an extremely productive R&D engine. With 25 years of biopharmaceutical R&D experience, Jennifer has led the development of therapeutic candidates from discovery to the market and established productive partnerships and alliances. Prior to joining Agenus, she held leadership positions at Bristol-Myers Squibb and at the Harvard Clinical Research Institute (Baim). Jennifer received her PhD in Cellular, Biochemical, and Molecular Biochemistry from Tufts University in Boston.